These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. How an Inhibitor Bound to Subunit Interface Alters Triosephosphate Isomerase Dynamics. Kurkcuoglu Z; Findik D; Akten ED; Doruker P Biophys J; 2015 Sep; 109(6):1169-78. PubMed ID: 26190635 [TBL] [Abstract][Full Text] [Related]
23. Overexpression of trypanosomal triosephosphate isomerase in Escherichia coli and characterisation of a dimer-interface mutant. Borchert TV; Pratt K; Zeelen JP; Callens M; Noble ME; Opperdoes FR; Michels PA; Wierenga RK Eur J Biochem; 1993 Feb; 211(3):703-10. PubMed ID: 8436128 [TBL] [Abstract][Full Text] [Related]
24. Structure-based inhibitor screening: a family of sulfonated dye inhibitors for malaria parasite triosephosphate isomerase. Joubert F; Neitz AW; Louw AI Proteins; 2001 Nov; 45(2):136-43. PubMed ID: 11562943 [TBL] [Abstract][Full Text] [Related]
25. Closed conformation of the active site loop of rabbit muscle triosephosphate isomerase in the absence of substrate: evidence of conformational heterogeneity. Aparicio R; Ferreira ST; Polikarpov I J Mol Biol; 2003 Dec; 334(5):1023-41. PubMed ID: 14643664 [TBL] [Abstract][Full Text] [Related]
26. Potent and Selective Inhibitors of Trypanosoma cruzi Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget Activity. Aguilera E; Varela J; Birriel E; Serna E; Torres S; Yaluff G; de Bilbao NV; Aguirre-López B; Cabrera N; Díaz Mazariegos S; de Gómez-Puyou MT; Gómez-Puyou A; Pérez-Montfort R; Minini L; Merlino A; Cerecetto H; González M; Alvarez G ChemMedChem; 2016 Jun; 11(12):1328-38. PubMed ID: 26492824 [TBL] [Abstract][Full Text] [Related]
27. Design, creation, and characterization of a stable, monomeric triosephosphate isomerase. Borchert TV; Abagyan R; Jaenicke R; Wierenga RK Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1515-8. PubMed ID: 8108439 [TBL] [Abstract][Full Text] [Related]
28. Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity. Alvarez G; Aguirre-López B; Varela J; Cabrera M; Merlino A; López GV; Lavaggi ML; Porcal W; Di Maio R; González M; Cerecetto H; Cabrera N; Pérez-Montfort R; de Gómez-Puyou MT; Gómez-Puyou A Eur J Med Chem; 2010 Dec; 45(12):5767-72. PubMed ID: 20889239 [TBL] [Abstract][Full Text] [Related]
29. Molecular docking and molecular dynamics simulation studies of Trypanosoma cruzi triosephosphate isomerase inhibitors. Insights into the inhibition mechanism and selectivity. Minini L; Álvarez G; González M; Cerecetto H; Merlino A J Mol Graph Model; 2015 May; 58():40-9. PubMed ID: 25829097 [TBL] [Abstract][Full Text] [Related]
30. A guide to the effects of a large portion of the residues of triosephosphate isomerase on catalysis, stability, druggability, and human disease. Olivares-Illana V; Riveros-Rosas H; Cabrera N; Tuena de Gómez-Puyou M; Pérez-Montfort R; Costas M; Gómez-Puyou A Proteins; 2017 Jul; 85(7):1190-1211. PubMed ID: 28378917 [TBL] [Abstract][Full Text] [Related]
31. Structures of Plasmodium falciparum triosephosphate isomerase complexed to substrate analogues: observation of the catalytic loop in the open conformation in the ligand-bound state. Parthasarathy S; Balaram H; Balaram P; Murthy MR Acta Crystallogr D Biol Crystallogr; 2002 Dec; 58(Pt 12):1992-2000. PubMed ID: 12454456 [TBL] [Abstract][Full Text] [Related]
32. Crystallographic binding studies with triosephosphate isomerases: conformational changes induced by substrate and substrate-analogues. Wierenga RK; Borchert TV; Noble ME FEBS Lett; 1992 Jul; 307(1):34-9. PubMed ID: 1639191 [TBL] [Abstract][Full Text] [Related]
34. Crystal structure of recombinant chicken triosephosphate isomerase-phosphoglycolohydroxamate complex at 1.8-A resolution. Zhang Z; Sugio S; Komives EA; Liu KD; Knowles JR; Petsko GA; Ringe D Biochemistry; 1994 Mar; 33(10):2830-7. PubMed ID: 8130195 [TBL] [Abstract][Full Text] [Related]
35. Structure-based protein engineering efforts with a monomeric TIM variant: the importance of a single point mutation for generating an active site with suitable binding properties. Alahuhta M; Salin M; Casteleijn MG; Kemmer C; El-Sayed I; Augustyns K; Neubauer P; Wierenga RK Protein Eng Des Sel; 2008 Apr; 21(4):257-66. PubMed ID: 18239072 [TBL] [Abstract][Full Text] [Related]
36. Using evolutionary changes to achieve species-specific inhibition of enzyme action--studies with triosephosphate isomerase. Gómez-Puyou A; Saavedra-Lira E; Becker I; Zubillaga RA; Rojo-Domínguez A; Pérez-Montfort R Chem Biol; 1995 Dec; 2(12):847-55. PubMed ID: 8807818 [TBL] [Abstract][Full Text] [Related]
37. Anatomy of a conformational change: hinged "lid" motion of the triosephosphate isomerase loop. Joseph D; Petsko GA; Karplus M Science; 1990 Sep; 249(4975):1425-8. PubMed ID: 2402636 [TBL] [Abstract][Full Text] [Related]
38. 1,2,4-thiadiazol-5(4H)-ones: a new class of selective inhibitors of Trypanosoma cruzi triosephosphate isomerase. Study of the mechanism of inhibition. Alvarez G; Aguirre-López B; Cabrera N; Marins EB; Tinoco L; Batthyány CI; de Gómez-Puyou MT; Puyou AG; Pérez-Montfort R; Cerecetto H; González M J Enzyme Inhib Med Chem; 2013 Oct; 28(5):981-9. PubMed ID: 22803666 [TBL] [Abstract][Full Text] [Related]
39. Structure of the triosephosphate isomerase-phosphoglycolohydroxamate complex: an analogue of the intermediate on the reaction pathway. Davenport RC; Bash PA; Seaton BA; Karplus M; Petsko GA; Ringe D Biochemistry; 1991 Jun; 30(24):5821-6. PubMed ID: 2043623 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of enolase: the crystal structures of enolase-Ca2(+)- 2-phosphoglycerate and enolase-Zn2(+)-phosphoglycolate complexes at 2.2-A resolution. Lebioda L; Stec B; Brewer JM; Tykarska E Biochemistry; 1991 Mar; 30(11):2823-7. PubMed ID: 2007121 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]